December 16, 2019 - A study published in The Lancet Infectious Diseases reports that a team of European researchers developed a chlamydia vaccine that was proven safe and effective in an early trial.
Disclaimer: This is general medical information and not specific medical advice. It does not and should not replace diagnosis or treatment by your healthcare provider. If you are seeking personal recommendations, advice, and/or treatment, please consult your physician. If you have an emergency, you should contact 911 or go to the nearest Emergency Room.
- Chlamydia is the most common bacterial sexually transmitted infection (STI) globally. Although most cases show no symptoms, 1 in 6 cases progresses to pelvic inflammatory disease, which can lead to infertility, pelvic pain, and ectopic pregnancy.
- No vaccine has been developed for chlamydia before. Chlamydia is currently treated with antibiotics and screened for with STI testing.
- This trial, which showed a desired immune response against chlamydia bacteria in 35 healthy participants, is very promising.
- However, further trials are needed before a vaccine can be deemed successful, including testing the vaccine’s success in people who already have chlamydia exposure. Vaccines commonly spend about 10-20 years in development, so this vaccine may not be commercially available any time soon.
You can read the original article here.